Mineralys Therapeutics In... (MLYS)
NASDAQ: MLYS
· Real-Time Price · USD
14.62
0.49 (3.47%)
At close: Aug 15, 2025, 12:50 PM
3.47% (1D)
| Bid | 14.63 |
| Market Cap | 969.44M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -188.51M |
| EPS (ttm) | -3.56 |
| PE Ratio (ttm) | -4.11 |
| Forward PE | -4.15 |
| Analyst | Buy |
| Ask | 14.69 |
| Volume | 424,317 |
| Avg. Volume (20D) | 868,579.7 |
| Open | 14.17 |
| Previous Close | 14.13 |
| Day's Range | 14.16 - 15.00 |
| 52-Week Range | 8.24 - 18.38 |
| Beta | -0.30 |
About MLYS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MLYS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MLYS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+2.45%
Mineralys Therapeutics shares are trading higher a...
Unlock content with
Pro Subscription
2 months ago
-1.44%
MLYS stock has given up its prior gain. Mineralys Therapeutics shares were trading higher after the company announced it presented Launch-HTN data at ESH 2025 and demonstrated its efficacy for over 1,000 patients.
